

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
Breast Cancer Steering Committee (BCSC)											
ACOSOG_Z11103 (A011106)	2&3	APPROVED; Pending with Revisions	ALternate approaches for clinical stage II and III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) Study (w/ BIQSFP)	Cynthia X. Ma, MD, PhD	3/30/2011; 5/23/2011 (rev 1); 06/08/211 (rev 2)	4/20/2011	6/15/2011	In Review 06/27/2012			Ki67
ALLIANCE_A011202	3	APPROVED	A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant	Judy C. Boughey, MD	3/26/2012	4/18/2012	N/A				N/A
NSABP/RTOG #9353	3	APPROVED; Pending with Revisions	A Randomized Phase III Clinical Trial Evaluating the Role of Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Documented Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy	Eleftherios Mamounas, MD, MPH (NSABP) Julia White, MD (RTOG)	3/27/2012; 5/31/2012	4/18/2012	6/20/2012				N/A
ECOG_E2108	3	APPROVED; Pending with Revisions	A Randomized Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer	Seema Khan, MD	4/30/2009	6/16/2009	N/A	10/26/2010	2/8/2011	102	880
NCIC CTG_MA.32	3	APPROVED; Pending with Revisions	A Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (w/ BIQSFP)	Pam Goodwin, MD	3/25/2009; 07/14/2009 (rev)	4/23/2009	7/23/2009	3/26/2010	6/25/2010 [Closed to Accrual]	3649	Fatigue, Behavioral, & Health Outcomes
NSABP B-48 (8708)	3	APPROVED; Pending with Revisions	A Randomized Phase III Clinical Trial Evaluating Pathologic Complete Response in Patients with Palpable and Operable, Triple-Negative Breast Cancer Treated with Docetaxel and Cyclophosphamide Followed by Gemcitabine and Carboplatin with or without the PARP1 Inhibitor BSI-201	Steven A, Limentani, MD	10/28/2009	11/19/2009	2/17/2010	Withdrawn 06/22/2011			N/A
(NSABP B-49 (#9186)	3	APPROVED; Pending with Revisions	A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	Patrick J. Flynn, MD	9/28/2011	10/19/2011	12/21/2011	2/28/2012	4/4/2012	1089	N/A
RTOG-1005	3	APPROVED; Pending with Revisions	A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation with Conventional Fractionation plus Sequential Boost for Early-Stage Breast Cancer	Frank A. Vicini, MD, FACR	7/22/2010 10/13/2010 (rev)	8/18/2010	10/20/2010	5/2/2011	5/24/2011	970	N/A
RTOG-1119	2	APPROVED	Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer – A Collaborative Study of RTOG and KROG	Kim In Ah, MD, PhD	8/8/2011	9/15/2011	N/A	6/11/2012	7/26/2012	5	N/A
SWOG_S1007	3	APPROVED; Pending with Revisions	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-9 Positive Nodes, Hormone-responsive and HER2-negative Breast Cancer according to Recurrence Score (RS) (w/ BIQSFP)	Ana Maria Gonzalez-Angulo, MD	2/24/2010; 5/25/2010 (rev)	3/18/2010	6/16/2010	1/3/2011	01/15/2011	2695	Onco Type DX
SWOG_S1207	3	APPROVED	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (w/ BIQSFP)	Mariana Chavez Mac Gregor, MD, MSc	12/27/2011	1/19/2012	N/A	8/3/2012	8/3/2012	0	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
NSABP #9432	3	APPROVED; Pending with Revisions	A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation	Mothaffar Rimawi, MD	6/28/2012; 10/10/2012	7/19/2012	10/24/2012				N/A
ECOG_E2112	3	APPROVED; Pending with Revisions	A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Metastatic Breast Cancer	Roisin Connolly, MB, BCh	9/4/2012; 12/11/12	10/17/2012	12/19/2012				N/A
Brain Malignancy Steering Committee (BMSC)											
ALLIANCE_A071 101	2	APPROVED; Pending with Revisions	A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Trial Comparing Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine or Placebo in Combination with Bevacizumab (Avastin®) in the Therapy of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)	Andrew Parsa, MD, PhD	12/22/2011; 2/27/2012	1/12/2012	3/8/2012	In Review 06/07/2012	5/22/2013	0	N/A
COG_ACNS1022	2	APPROVED; Pending with Revisions	A Phase II Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Low-Grade CNS Gliomas	Kathy Warren, MD	12/27/2010	1/13/2011	3/10/2011	3/2/2012	3/19/2012	16	N/A
COG_ACNS1123	2	APPROVED; Pending with Revisions	Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors	Ute Bartels, MD	5/25/2011; 8/31/2011	7/14/2011	9/8/2011	5/15/2012	5/29/2012	43	N/A
PBTC-033 (C9073)	2	APPROVED; Pending with Revisions	A Feasibility and Phase II Study of ABT888, an oral poly(ADP-ribose) polymerase inhibitor, and concurrent radiation therapy, followed by ABT888 and temozolomide, in children with newly diagnosed high-grade or diffuse pontine gliomas (DIPG)	Jack Meng-Fen Su, MD	05/04/2011 (rev1)	3/10/2011	5/12/2011	In Review 11/14/2011	11/17/2011	7	N/A
RTOG-1205	2	APPROVED; Pending with Revisions	Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma	Christina Tsien, MD	12/15/2011	1/12/2012	3/8/2012	In Review 07/16/2012	12/20/2012	0	N/A
RTOG-1125	2&3	APPROVED; Pending with Revisions	Phase II/III Randomized, Double Blinded Placebo Controlled Trial Comparing Adjuvant Temozolomide and Ipilimumab with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma After Successful Completion of Concurrent Radiation and Temozolomide	Mark R. Gilbert, MD	7/20/2011; 10/06/2011 (rev)	8/11/2011	10/13/2011	6/22/2012			N/A
PBTC #9425/C106	2	APPROVED; Pending with Revisions	A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor (PNET) and Diffuse Intrinsic Pontine Glioma	Kathleen Dorris, MD	6/21/2012; 9/13/2012	7/12/2012	9/21/2012				N/A
COG_ACNS1221	2	APPROVED	A Phase II Study for the Treatment of Non-Metastatic Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age	Lucie LaFay-Cousin, MD	8/21/2012	9/21/2012	N/A				N/A
PBTC #9514	2	APPROVED	Phase II study of pegylated interferon α -2b for pediatric patients with unresectable or recurrent craniopharyngioma	Regina Jakacki, MD	11/13/2012	12/13/2012	N/A				N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
Clinical Imaging Steering Committee (CISC)											
9175 (ACRIN_6698)	3	APPROVED	Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And MoLecular Analysis)	Nola Hylton, PhD.	8/15/2011	9/13/2011	N/A	3/15/2012	8/27/2012	52	N/A
CALGB_71101 (A211201)	3	APPROVED	Change in Mammographic Density with Metformin Use: A Companion Study to NCIC study MA.32	Jennifer Eng-Wong, MD, MPH	7/25/2011	8/9/2011	N/A		8/22/2012	36	N/A
ACRIN_6702	2	APPROVED; Pending with Revisions	A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer	Savannah Partridge, PhD	8/30/2012; 2/12/2013	10/16/2012	2/19/2013				N/A
Gynecologic Steering Committee (GCSC)											
GOG_DTM0708	2	WITHDRAWN; Approved	A Randomized Phase II Evaluation of Volociximab (M200) plus Weekly Paclitaxel vs. Weekly Paclitaxel Alone in the Third-line Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GOG-0186 series)	Linda A. Duska, MD	N/A - sent directly to Uterine TF	9/11/2007	N/A	N/A	WD	NA	N/A
SWOG_S0903	2	WITHDRAWN; Approved	Randomized Phase II Study Evaluating Carboplatin/Paclitaxel Compared with Carboplatin/Paclitaxel and Everolimus in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in First Relapse	Lainie P. Martin, MD	3/29/2010	4/20/2010	N/A	In Review 07/29/2010	WD	NA	N/A
GOG_DTM0929	2	WITHDRAWN; Approved	A Phase II Study Of The Potent, Highly Selective Poly(Adp-Ribose) Polymerase (Parp) -1 And -2 Inhibitor Mk-4827 In The Treatment Of Persistent Or Recurrent High-Grade Serous Ovarian Cancer	Robert L. Coleman, MD	10/21/2010	11/16/2010	N/A	N/A	WD	NA	N/A
GOG_OVM0606	3	WITHDRAWN; Approved	A Randomized Phase III Trial of Neoadjuvant Carboplatin/ Paclitaxel vs. Carboplatin/Weekly Abraxane in Performance Status Challenged and Geriatric Patients	Thomas J. Herzog, MD	N/A - sent directly to Ovarian TF	11/6/2007	N/A	N/A	WD	NA	N/A
GOG-0238	2	APPROVED	A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Higinia R. Cardenes, MD, PhD	NOT A CONCEPT; Study came to PIO as Protocol; 12/12/2006	2/23/2007	N/A	5/11/2007	2/25/2008	63	N/A
LOI 8093 (GOG-0248)	2	APPROVED	Randomized Phase II Trial of Temsirolimus or the Combination of Hormonal Therapy Plus Temsirolimus in Women with Advanced or Recurrent Endometrial Carcinoma	Gini Fleming, MD	Not a CONCEPT; LOI; 4/6/2007	5/8/2007	N/A	7/28/2008	9/29/2008 [Closed to Accrual]	73	N/A
DTM0801 (GOG - 0186G)	2	APPROVED	A Randomized Phase II Evaluation of Oral Everolimus (RAD001) plus Bevacizumab vs. Oral Placebo plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	William P. Tew, MD	8/7/2008; 10/28/08 (rev)	11/18/2008	N/A	4/6/2009	12/27/2010 [Closed to Accrual]	150	N/A
DTM0905 (GOG - 0186I)	2	APPROVED	A Randomized Phase II Evaluation of Single Agent Bevacizumab (NSC #704865) and Combination Bevacizumab with Fosbretabulin in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	Bradley J. Monk, MD	9/29/2009	10/20/2009	N/A	2/22/2011	3/21/2011 [Closed to Accrual]	101	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
GOG-0213	3	APPROVED; Pending with Revisions	A Phase 3 Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab or in Combination with Bevacizumab Followed by Bevacizumab and Erlotinib and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian and Peritoneal Primary Cancer	Robert L. Coleman, MD	10/26/04; revision 1 - 6/14/05; revision 2 - 7/5/05; 8/16/06	9/28/2006	1/9/2007	10/19/2007	12/6/2007	742	N/A
UC-0704 (GOG-0258)	3	APPROVED	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Daniela Matei, MD	5/29/2007	7/9/2007	N/A	6/29/2009	6/29/2009	578	N/A
GOG-0204R-CVM-0704 (GOG-0240)	3	APPROVED	A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Krishnansu S. Tewari, MD	NOT A CONCEPT; Protocol; 05/31/07	6/25/2007	N/A	11/21/2008	4/6/2009 [Closed to Accrual]	452	N/A
UC-0701 (GOG-0261)	3	APPROVED	Randomized Phase III Trial of Carboplatin plus Paclitaxel versus Ifosfamide plus Taxol in Patients with Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus	Matthew A. Powell, MD	7/31/2007	8/7/2007	N/A	7/23/2009	8/17/2009	472	N/A
UC-0604 (2007) (GOG-0249)	3	APPROVED	Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer (w/ BIQSFP)	Scott McMeekin, MD	08/21/06; 10/09/07 (rev)	11/6/2007	N/A	12/1/2008	3/23/2009 [Closed to Accrual]	578	PROMIS 7 (HRQOL)
OVM0705 (GOG-0252)	3	APPROVED	Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Joan L. Walker, MD	12/14/2007	1/8/2008	N/A	7/20/2009	7/27/2009 [Closed to Accrual]	1548	N/A
OVM0703 (GOG-0255)	3	APPROVED	A Randomized Phase III Trial in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer with a Polyvalent Vaccine-KLH Conjugate + QS-21 versus QS-21	Paul Sabbatini, MD	4/22/2008	5/13/2008	N/A	2/19/2009	7/26/2010 [Closed to Accrual]	171	N/A
GOG-0241	3	APPROVED; Pending with Revisions	A Randomized Phase III Evaluation of Capecitabine and Oxaliplatin (Xelox) versus Carboplatin and Paclitaxel in Mucinous Adenocarcinoma of the Ovary	David M. Gershenson, MD	01/04/08; 04/16/08 (rev); 12/30/08 (rev); 02/04/10 (rev)	5/13/2008	1/20/2009	9/8/2010	10/12/2010	13	N/A
CVM0801 (GOG 0263)	3	APPROVED	Randomized Clinical Trial for Adjuvant Chemo-radiation in Post-operative Cervical Cancer Patients with Intermediate Risk Factors	Sang Young Ryu, MD	03/26/08; 04/24/08 (rev); 01/30/09 (rev)	2/17/2009	N/A	4/1/2010	4/12/2010	122	N/A
OVM0813 (GOG 0262)	3	APPROVED; Pending with Revisions	A Randomized Phase III Trial of Every-Three-Weeks versus Dose Dense Weekly Paclitaxel and Carboplatin plus Concurrent Bevacizumab in the Treatment of Primary Suboptimal Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma	John K. Chan, MD	11/10/2008; 3/10/2009 (rev)	12/1/2008	1/20/09; 3/17/09; 4/7/09	7/2/2010	9/27/2010	773	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
CVM1004 (ANZGOG-0902; GOG-0274)	3	APPROVED	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: GOG COLLABORATION WITH THE OUTBACK TRIAL (ANZGOG 0902)	Kathleen Moore, MD	3/30/2010 7/2/2010 (rev)	4/20/2010	7/20/2010	7/22/2011	1/9/2012	64	N/A
GOG -UC1009 (GOG-0277)	3	APPROVED; Pending with Revisions	A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. Letrozole for Early Stage High Grade Uterine Leiomyosarcoma	Martee L. Hensley, MD	3/23/2011; 06/22/2011 - (rev)	4/19/2011	7/12/2011	2/6/2012	6/4/2012	1	N/A
GOG - UC1005 (GOG-0275)	3	APPROVED	A Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-day Methotrexate for the Treatment of Low-risk Gestational Trophoblastic Neoplasia	Julian C. Schink, MD	4/28/2011	5/17/2011	N/A	2/8/2012	6/18/2012	9	N/A
DTM0720 (GOG-0250)	2b	APPROVED	Randomized Phase IIB Evaluation of Gemcitabine-Docetaxel with or without Bevacizumab for Advanced or Recurrent Uterine Leiomyosarcoma	Martee L. Hensley, MD	2/25/2008; 03/17/2006 (rev)	4/7/2008	N/A	10/19/2009	11/9/2009	106	N/A
RTM0602 (GOG 0264)	2b	APPROVED; Pending with Revisions	A Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage Sex Cord-Stromal Tumors of the Ovary	Jubilee Brown, MD	4/28/2009	5/19/2009	N/A	12/29/2009	2/8/2010	14	N/A
DTM1003 (GOG-0186J)	2b	APPROVED	A Randomized Phase IIB Evaluation of Pazopanib versus Weekly Paclitaxel plus Pazopanib versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	Debra L. Richardson, MD	6/15/2010	7/20/2010	N/A	11/02/2011	12/12/2011 <i>[Closed to Accrual]</i>	102	N/A
GOG - 0270		APPROVED; Pending with Revisions	Groningen International Study on Sentinel Nodes in Vulvar Cancer (Groinss-V) II: An Observational Study	Brian M. Slomovitz, MD	11/24/2010 05/10/11 (rev)	1/18/2011	5/31/2011	12/15/2011	1/3/2012	26	N/A
NCIC CTG_OV.21	3	APPROVED	A Phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy	Helen Mackay, MD	11/9/2009	11/17/2009	N/A	11/1/2010	9/11/2009	151	N/A
RTOG-0724	3	APPROVED; Pending with Revisions	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy	Anuja Jhingran, MD	9/25/2007; 3/24/2009	6/9/2008	9/9/2008	8/10/2009	9/16/2009	62	N/A
SWOG_S0904	2	APPROVED	Randomized Phase II Study of Docetaxel Followed by ZD6474 (Vandetanib) vs. Docetaxel plus ZD6474 in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	Robert L. Coleman, MD	8/19/2008; 10/28/2008 (rev)	11/18/2008	N/A	3/17/2009	3/15/2010 <i>[Closed to Accrual]</i>	131	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
GOG_RTM1104	2 & 3	APPROVED	A Randomized Phase II/III Study to Assess the Efficacy of MEK Inhibitor GSK1120212 in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer	David M. Gershenson, MD	8/2/2012	8/21/2012	N/A				N/A
GOG_DTM1212	2 & 3	APPROVED; Pending with Revisions	A Randomized Phase II/III Evaluation of Paclitaxel/Carboplatin/Metformin versus Paclitaxel/Carboplatin/Placebo in Advanced and Recurrent Endometrial Cancer Patients	Victoria Bae-Jump, MD	8/31/2012; 11/02/2012	9/18/2012	11/20/2012				N/A
Gastrointestinal Steering Committee (GISC)											
ACOSOG Z6051	3	APPROVED; Pending with Revisions	A Phase III Trial Comparing Laparoscopic-Assisted Rectal Resection (LARR) to Open Resection for Rectal Cancer	James Fleshman, MD	4/2/2007	5/21/2007	7/16/2007	7/22/2008	8/15/2008	462	N/A
CALGB-80701	2	APPROVED; Pending with Revisions	A Phase II Randomized Study of Temozolomide or Temozolomide + Bevacizumab in Patients with Advanced Pancreatic Neuroendocrine Tumors	Matt Kulke, MD	12/3/2007; 05/12/08 (rev)	12/17/2007	5/19/2008	10/15/2010	10/15/2010 [Closed to Accrual]	148	N/A
CALGB-80803	2	APPROVED; Pending with Revisions	Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (w/ BIQSFP)	Kathryn A. Goodman, MD	4/20/2010	6/21/2010	8/16/2010	4/4/2011	7/15/2011	61	Central pathology & PET/CT
CALGB-81003	2	APPROVED	Phase IB/Randomized Phase II Study of Folfirinox plus AMG-479 or placebo in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma	Brian M. Wolpin, MD, MPH	2/17/2011	3/28/2011	N/A	11/4/2011	8/2/2012 (administratively complete)	0	N/A
CALGB-81103	2	APPROVED	Prospective Randomized Phase II Trial of Pazopanib Versus Placebo in Patients with Progressive Carcinoid Tumors	Emily Bergsland, MD	12/13/2011	1/30/2012	N/A				N/A
CALGB-80802	3	APPROVED; Pending with Revisions	Phase II/III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)	Abou-Alfa Ghassan, MD	4/10/2008; 08/07/08 (rev)	5/19/2008	8/18/2008	11/2/2009	2/15/2010	207	N/A
CALGB-80702	3	APPROVED; Pending with Revisions	A 2 x 2 Phase III Trial of Celecoxib and Vitamin D in Addition to Standard Chemotherapy for Stage III Colon Cancer	Jeffrey A. Meyerhardt, MD	7/7/2008, 10/13/2008, 2/21/2009	7/21/2008	11/17/2008; 2/27/2009	6/15/2010	6/22/2010	1092	N/A
ECOG_E7208	2	APPROVED; Pending with Revisions	A Randomized Phase II Study of Irinotecan with Cetuximab Plus/Minus IMC-1121B in Metastatic Colorectal Cancer Patients Progressing on Bevacizumab-Containing Chemotherapy	Howard S. Hochster, MD	2/3/2009	2/27/2009	5/18/2009	2/22/2010	10/8/2010 (Temporarily closed to Accrual)	35	N/A
ECOG_E1208	3	APPROVED; Pending with Revisions	A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.	John Kauh, MD	5/27/2008; 6/9/2008 (rev); 9/8/2007 (rev)	6/16/2008	9/15/2008	10/5/2009	10/28/2009	158	N/A
NCCTG_N0949	3	APPROVED; Pending with Revisions	Randomized Phase III Trial of mFOLF0X7 Plus Bevacizumab Versus 5-Fluorouracil or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients (≥75Years Old) with Metastatic Colorectal Cancer	Alex Grothey, MD	3/29/2010	4/19/2010	6/21/2010	12/23/2010	01/21/2011 [Closed to Accrual]	30	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
ECOG_E2211	2	APPROVED; Pending with Revisions	A Randomized Study of Temozolomide or Temozolomide + Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors	Pamela L. Kunz, MD	2/28/2012	3/19/2012	5/21/2012	In Review 7/27/2012	5/2/2013	1/1/1904	N/A
NCCTG N1048/ CALGB 81001/ ACOSOG Z6092	2&3	APPROVED; Pending with Revisions	A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	Deborah Schrag MD (CALGB) , Alessandro Fichera (ACOSOG) Robert McWilliams Mayo Clinic (NCCTG)	1/20/2011	2/28/2011	4/4/2011	10/14/2011	1/13/2012	37	N/A
NSABP-C-11 (8358)	3	APPROVED; Pending with Revisions	Phase III Trial Evaluating the Role of Perioperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases	Michael Choti, MD	12/22/2008; 04/13/09 (rev)	1/26/2009	4/20/2009	7/29/2010	8/23/2010 [Administratively Complete]	8	N/A
RTOG-0436	3	APPROVED; Pending with Revisions	A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Locally Advanced Esophageal Cancer	Mohan Suntharalingam, MD	09/20/06 (rev); 12/12/06 (rev2)	10/16/2006	12/18/2006	10/27/2007; 12/11/2007	6/30/2008 [Closed to Accrual]	344	N/A
RTOG-0848	3	APPROVED; Pending with Revisions	Gemcitabine, With and Without Erlotinib, Followed By a Second Randomization With and Without Chemoradiation, as Adjuvant Treatment For Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study	Ross Abrams, MD	8/8/2008; 11/10/2008	8/18/2008	11/17/2008	10/23/2009	11/17/2009	264	N/A
RTOG-1010	3	APPROVED; Pending with Revisions	A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2 Overexpressing Esophageal Adenocarcinoma (w/ BIQSFP)	Howard Safran, MD	09/25/2009; 10/23/2009 (rev)	11/16/2009	1/11/2010	8/11/2010	12/30/2010	286	HER2
RTOG-1112	2&3	APPROVED; Pending with Revisions	Randomized Phase II/III Study of Sorafenib versus Sorafenib and Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma	Laura A. Dawson, MD	7/25/2011; 10/07/2011 (rev)	8/15/2011	10/17/2011	In Review 5/25/2012	4/24/2013	0	N/A
SWOG_S1115	2	APPROVED; Pending with Revisions	Randomized Phase II Clinical Trial of AZD-6244 and MK-2206 vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy	Vincent Chung, MD	6/1/2011	7/18/2011	8/15/2011	7/27/2012	8/15/2012	14	N/A
SWOG_S1201	2	APPROVED	A Randomized Phase II Pilot Study Prospectively Assigning Treatment for Patients Based on ERCC1 for Advanced/Metastatic Gastric Cancer or Gastroesophageal (GE) Junction Cancer (w/ BIQSFP)	Syma Iqbal, MD	6/27/2011	8/15/2011	N/A	12/14/2011	2/8/2012	59	ERCC-1
USMCI_8214	3	APPROVED	A Phase III Trial Comparing Best Available Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin-C + Best Available Systemic Therapy in Patients with Limited Peritoneal Dissemination of Colon Adenocarcinoma	Alex Stojadinovic, MD, Jesus Esquivel, MD	12/5/2007	12/17/2007	N/A	7/7/2010	8/23/2010 [Closed to Accrual]	1	N/A
RTOG-1201	2	APPROVED; Pending with Revisions	A SMAD4-driven Phase II Randomized Trial of High Versus Standard Intensity Local or Systemic Therapy for Unresectable Pancreatic Cancer (w/ BIQSFP)	Edgar Ben-Josef, MD	5/25/2012; 8/29/2012	6/18/2012	9/24/2012				SMAD-4

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
ECOG_E1212	2	APPROVED	Randomized Phase II Study of mFOLFOX6 +/- Tivantinib (ARQ 197) in the First Line Treatment of Patients with Her2Neu Negative and High c-Met Expressing Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Lakshmi Rajdev M.D., M.S	6/26/2012	7/16/2012	N/A				N/A
ECOG_E2212	2	APPROVED; Pending with Revisions	A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver	Steven K. Libutti, MD, FACS	9/24/2012; 12/10/2012	10/15/2012	12/21/2012				N/A
SWOG_S1313	2	APPROVED	A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma	Ramesh K. Ramanathan, MD	1/25/2013	2/25/2013	N/A				N/A
Genitourinary Steering Committee (GUSC)											
CALGB-90802	3	APPROVED	Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors.	George K. Philips, MD	7/21/2008	9/17/2008	N/A	8/19/2010	9/15/2010 [Closed to Accrual]	75	N/A
ECOG_E2810	3	APPROVED; Pending with Revisions	Randomized, double-blind phase III study of pazopanib vs. placebo in subjects with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy	Leonard J. Appleman, MD, PhD	3/30/2011; 6/8/2011 (rev)	4/20/2011	7/20/2011	3/19/2012	8/8/2012	4	N/A
CALGB_90901	3	WITHDRAWN; Approved	A Randomized Phase III Study of ixabepilone, mitoxantrone and prednisone versus mitoxantrone and prednisone alone in patients with castration resistant prostate cancer previously treated with docetaxel chemotherapy.	Charles Ryan, MD	4/1/2009	6/17/2009	8/19/2009	No protocol rec'd	WD	N/A	N/A
RTOG 0815	3	APPROVED; Pending with Revisions	A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer	Alvaro A. Martinez, MD	7/11/08 11/7/08	8/20/2008	11/19/2008	6/18/2009	9/14/2009	913	N/A
RTOG-0924	3	APPROVED; Pending with Revisions	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial	Mack Roach III, MD	6/2/2010; 10/14/2010 (rev)	7/21/2010	10/20/2010	5/24/2010	7/7/2011	341	N/A
RTOG-1115	3	APPROVED	Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700	M. Dror Michaelson, MD	2/14/2011	5/4/2011	N/A	2/28/2012	5/1/2012	50	N/A
SWOG_S0931	3	APPROVED	EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study	Christopher Ryan, MD	4/3/2009	5/20/2009	N/A	3/15/2010	4/1/2011	413	N/A
SWOG_S1011	3	APPROVED	Prospective Evaluation Of The Benefit Of A Standard Versus An Extended Pelvic Lymphadenectomy Performed At Time Of Radical Cystectomy For Bladder Cancer With Adjuvant Chemotherapy Administration For Node Positive Disease	Seth Paul Lerner, MD	3/31/2010	4/21/2010	N/A	09/30/2010; 01/07/2011 (rev)	8/1/2011	173	N/A
SWOG_S1216	3	APPROVED	A Phase III Randomized Trial Comparing LHRHa + TAK-700 with LHRHa + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer	Neeraj Agarwal, MD	3/1/2012	3/21/2012	N/A		3/6/2013	9	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
ALLIANCE_A031201	3	APPROVED (with recommendations)	A Phase III Trial of MDV3100 vs. MDV3100 and Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer (w/ BIQSFP)	Michael J. Morris	6/26/2012	7/18/2012	N/A				PET/CT
RTOG-1218	2	APPROVED; Pending with Revisions	Conventional versus Hypofractionated Postprostatectomy Radiotherapy for Adverse Pathologic Features or PSA Recurrence	Mark K. Buyyounouski, MD., MS	11/26/2012; 02/13/2013	12/19/2012	3/20/2013				N/A
SWOG_S1314	2	APPROVED	A Randomized Phase II Study of CO-eXpression Extrapolation (COXEN)-Directed Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer (w/BIQSFP)	Thomas W. Flaig, MD	2/27/2013	3/20/2013	N/A				COXEN-Co-eXpression Extrapolation & Whole - Genome DASL HT
Head & Neck Steering Committee (HNSC)											
ACRIN_6685 (#8270)	2	APPROVED; Pending with Revisions	FDG PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck	Val Lowe, MD	4/30/2008	11/3/2008	2/23/2009	9/2/2009	4/1/2010	167	N/A
ECOG_E1311	2	APPROVED; Pending with Revisions	A Randomized Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence	Christine H. Chung, MD	3/12/2012	4/9/2012	8/6/2012				N/A
RTOG-1008	2	APPROVED	A Randomized Phase II Study of Adjuvant Concurrent Chemotherapy and Radiation in Resected High-Risk Malignant Salivary Gland Tumors	Cristina P. Rodriguez, MD; David Adelstein, MD	2/1/2010	5/3/2010	N/A	9/17/2010	11/3/2010	61	N/A
RTOG-0920	3	APPROVED	Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck	Mitchell Machtay, MD	1/9/2008; 5/8/2008	2/1/2008	5/5/08; 8/4/08	7/22/2009	11/5/2009	281	N/A
RTOG-1016	2&3	APPROVED; Pending with Revisions	Phase II-III Trial of Moderate De-Escalation of Chemotherapy and Radiation in Favorable Risk, Locally Advanced, HPV-Associated Oropharynx Cancer (w/ BIQSFP)	Andy Trotti, MD	3/22/2010	4/12/2010	7/12/2010	2/15/2011	6/9/2011	613	p16
RTOG-1216	2&3	APPROVED	Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and Neck (w/ BIQSFP)	Paul Harari, MD; David Rosenthal	4/16/2012	5/23/2012	N/A		3/18/2013	1	p16 + EGFR
ECOG_E3311	2	APPROVED; Pending with Revisions	Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT with Biomarker Correlatives in Resectable p16+ Locally Advanced Oropharynx Cancer	Robert L. Ferris, MD, PhD	5/15/2012; 9/24/2012	6/25/2012	10/22/2012				N/A
RTOG-1221	2	APPROVED	Randomized Phase II Trial of Transoral Endoscopic Head and Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer (w/ BIQSFP)	Floyd Christopher Holsinger, MD, FACS	8/20/2012	9/24/2012	N/A				MBS
RTOG-1305	2&3	APPROVED	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Nancy Lee, MD	3/11/2013	4/1/2013	N/A				N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
Leukemia Steering Committee (LKSC)											
CALGB-11002	2	APPROVED	A Randomized Phase II Trial of Decitabine-based Induction Strategies for Patients ≥ 60 Years Old with Acute Myeloid Leukemia	Gail J. Roboz, MD	6/24/2010; 9/20/2010 (Rev)	7/27/2010	9/28/2010	8/15/2011	11/16/2011 [Closed to Accrual]	126	N/A
SWOG_S1203	3	APPROVED; Pending with Revisions	A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or Without Vorinostat in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) (w/ BIQSFP)	Guillermo Garcia-Manero, MD	3/7/2012; 5/2/2012	3/27/2012	5/22/2012		2/12/2013	12	FISH and Cytogenetics for t(8;21), inv(16)/t(16;16), and t(15;17)
SWOG_S1117	2	APPROVED	A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine in Combination with Vorinostat vs. Azacitidine Alone for Higher-Risk Myelodysplastic Syndromes (MDS)	Mikkael A. Sekeres, MD	6/8/2011	6/28/2011	N/A	1/20/2012	3/1/2012	93	N/A
ECOG_E1912	2&3	APPROVED	A Randomized Phase II/III Study of PCI-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)	Tait Shanafelt, MD	4/3/2012	4/24/2012	N/A	In Review 8/6/2012			N/A
ALLIANCE_A041202	3	APPROVED	A Randomized Phase III Study of Chlorambucil Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL)	Jennifer Woyach, MD	5/29/2012	6/26/2012	N/A				N/A
ECOG_E1910	3	APPROVED	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Acute Lymphoblastic Leukemia in Adults (w/ BIQSFP)	Mark R. Litzow, MD	6/5/2012	6/26/2012	N/A				PET/CT
Lymphoma Steering Committee (LYSC)											
CALGB-51101	2	APPROVED	Randomized trial of myeloablative versus non-myeloablative consolidation chemotherapy for newly diagnosed primary CNS B-cell lymphoma	Tracey Batchelor, MD	5/23/2011	7/8/2011	N/A	12/27/2011	6/15/2012	3	N/A
ECOG_E2410	2	APPROVED	Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)	Ranjana Advani, MD	1/21/2011	2/11/2011	N/A	6/21/2011	4/2/2012	0	N/A
E1411 [formerly ECOG E1410]	2	APPROVED	Intergroup Randomized Phase 2 Four Arm Study In Patients ≤ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV → R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)	Mitchell Smith, MD, PhD	2/18/2011	3/11/2011	N/A	7/29/2011	5/22/2012	27	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
ECOG_1410	2	WITHDRAWN; Approved	Intergroup Randomized Phase 2 Three-Arm Study In Patients \leq 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine (R - B), Arm B = Rituximab + Bendamustine + Bortezomib (R - B - V), or Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (R - B \rightarrow L - R)	Mitchell Smith, MD, PhD	9/1/2010	10/8/2010	N/A	N/A	WD	N/A	N/A
SWOG_S1001	2	APPROVED; Pending with Revisions	A Phase II Trial of PET-directed Therapy for Early Stage Diffuse Large B-cell Lymphoma	Daniel O. Persky, MD	10/6/2010; 01/24/2011	12/10/2010	2/11/2011	5/16/2011	7/18/2011	40	N/A
SWOG_S1106	2	APPROVED	A Randomized Phase II Trial of R-HCVAD-MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Previously Untreated Patients \leq 65 Years of Age With Mantle Cell Lymphoma	Steven H. Bernstein, MD	1/28/2011	3/11/2011	N/A	7/29/2011	10/1/2011	43	N/A
ECOG_E1412	2	APPROVED; Pending with Revisions	Randomized Phase II Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma	Grzegorz S. Nowakowski MD	5/18/2012; 7/6/2012	6/8/2012	8/10/2012				N/A
Myeloma Steering Committee (MYSC)											
ECOG_E1A10	2	APPROVED; Pending with Revisions	A Randomized Selection Phase II Study of Rituximab, Bortezomib, and Dexamethasone and Rituximab, RAD001, and Dexamethasone in Previously Untreated, Symptomatic Waldenstrom's Macroglobulinemia	Leonard T. Heffner, Jr.	5/13/2010; 5/28/2010	7/6/2010	9/7/2010	5/27/2011	7/20/2011	3	N/A
ECOG_E1A11	3	APPROVED; Pending with Revisions	Randomized Phase 3 Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) in Patients with Newly Diagnosed Symptomatic Multiple Myeloma	Shaji Kumar, MD	1/19/2012; 4/24/2012	3/6/2012	5/1/2012	In Review 7/31/2012			N/A
SWOG_S1304	2	APPROVED	A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-XXXX) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease	Sikander Ailawadhi, MD	9/11/2012	10/2/2012	N/A				N/A
ALLIANCE_A061 202	1&2	APPROVED; Pending with Revisions	A Phase 1/2 study of Pomalidomide, Dexamethasone and MLN9708 vs. Pomalidomide and Dexamethasone for Patients with Relapsed and Relapsed/Refractory Multiple Myeloma Previously Treated with Proteasome Inhibitor-Based Therapy and Resistant to or Intolerant of Lenalidomide	Peter Voorhees, MD	9/13/2012; 12/07/2012	11/6/2012	1/8/2013				N/A
Pediatric & Adolescent Solid Tumor Steering Committee (PASTSC)											
COG_ADV1122	2	APPROVED	A Phase II Trial of Pazopanib (NSC# 737754, IND# 75648) in Children with Refractory Solid Tumors	Alice Lee, MD	8/19/2011	9/26/2011	N/A				N/A
COG_ANBL1221	2	APPROVED	Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Chimeric 14.18 Antibody (ch14.18) in Children with Relapsed/Refractory Neuroblastoma	Rajen Mody, MD, MS	1/5/2012	1/23/2012	N/A	In Review 5/18/2012	2/12/2013	2	N/A
COG_ANBL12P1	obs	APPROVED	Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma	Meaghan Granger, MD	2/1/2012	2/27/2012	N/A	In Review 5/04/2012	4/8/2013	0	N/A
COG_ANBL1122	2	WITHDRAWN; Approved	Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Bevacizumab (Avastin) in Children with Relapsed Neuroblastoma	Rajen Mody, MD, MS	6/29/2011	7/25/2011	N/A	N/A	WD	N/A	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
COG_ARST1221	2	APPROVED; Pending with Revisions	A Feasibility Study of Ifosfamide and Doxorubicin (ID) and Radiotherapy with or without Pazopanib in Patients with Newly Diagnosed Unresected Intermediate- or High-Risk Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)	Aaron Weiss, DO	1/3/2012; 5/21/2012	1/23/2012	5/29/2012				N/A
COG_AEWS1221	2	APPROVED	Randomized Phase II Selection Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody AMG 479 to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma	Steven DuBois, MD	3/5/2012	4/9/2012	N/A				N/A
COG_ANBL1232	3	APPROVED; Pending with Revisions	Response- and Biology-Based Therapy for Patients with Non-High-Risk Neuroblastoma (w/ BIQSFP)	Holly Meany, MD	1/7/2013; 4/8/2013	2/6/2013	4/22/2013				MYCN FISH, DNA FLOW, SNP array, central path review
COG_ARET12P1	2	APPROVED; Pending with Revisions	A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma	Murali Chintagumpala, MD	2/1/2013; 5/21/2013	2/25/2013	5/30/2013				N/A
COG_ADVL1321	2	APPROVED	A Phase II Trial of Imetelstat (GRN163L, NSC# 754228, IND# 110934) in Children with Refractory Solid Tumors	Patrick A. Thompson, MD	2/4/2013	2/25/2013					N/A
Pediatric Leukemia & Lymphoma Steering Committee (PLLSC)											
COG_ANHL1131	2&3	APPROVED; Pending with Revisions	Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B- AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients.	Thomas G. Gross, MD, Ph.D	4/29/2011; 7/22/2011	6/3/2011	8/5/2011	4/24/2012	6/1/2012	17	N/A
COG_ASCT1221	2	APPROVED; Pending with Revisions	A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML) (w/ BIQSFP)	Adam Peterson, MD	1/17/2012; 3/30/2012	2/3/2012	4/6/2012	In Review 6/27/2012			DNA sequencing
COG_ANHL12P1	2	APPROVED; Pending with Revisions	A Pilot Study of Brentuximab Vedotin (NSC# 749710, IND pending) and Crizotinib (NSC#749005, IND pending) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)	Eric Lowe, MD	7/13/2012; 9/28/2012	8/3/2012	10/5/2012				N/A
Symptom Management & Quality of Life Steering Committee (SxQLSC)											
GOG 0257	3	APPROVED; Revise & Resubmit	A Randomized, Double-Blind, Placebo Controlled Trial Using Acetyl L-Carnitine (ALCAR) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients with Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	David Kushner, MD	9/26/2008	11/18/2008	4/14/2009	12/6/2011	4/16/2012	0	N/A
HLMCC-0806 SCUSF-0806	2	APPROVED; Revise & Resubmit	Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin)	Maya Guglin, MD	8/25/2008	10/14/2008	1/13/2009	8/31/2009	3/1/2010	279	N/A
NCCTG_N08C3	3	APPROVED	Phase III Double-Blind, Placebo Controlled Study of Gabapentin for the Treatment of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy	Deborah Barton, RN, PhD	2/12/2008	3/11/2008	N/A	1/28/2009	4/17/2009 [Closed to Accrual]	430	N/A

NCI Scientific Steering Committee Approved Concepts (2006 - May 31, 2013)

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
NCCTG_N08C7	3	APPROVED	Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes	Deborah Barton, RN, PhD	5/14/2008	6/10/2008	N/A	5/27/2009	10/9/2009 <i>[Closed to Accrual & Treatment]</i>	210	N/A
NCCTG-N08CB	3	APPROVED; Revise & Resubmit	A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity	Charles Loprinzi, MD	9/12/2008	10/14/2008	1/13/2009	3/29/2010	6/22/2010 <i>[Closed to Accrual]</i>	362	N/A
NCCTG_N09C6	3	APPROVED; Revise & Resubmit	Phase III Double-Blind Cross-over Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy and/or Chemotherapy	James L. Leenstra MD; Robert C. Miller, MD	7/24/2009	9/8/2009	12/8/2009	6/9/2010	12/17/2010	162	N/A
NCCTG_N10C1	3	APPROVED	Vaginal DHEA for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study	Debra Barton MD	5/7/2010	5/11/2010	N/A	5/18/2011	7/29/2011 <i>[Closed to Accrual]</i>	464	N/A
NCCTG_N10C2	3	APPROVED; Revise & Resubmit	Phase III Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes	Haeseong Park, MD, MPH	8/12/2010; 3/3/2011 (rev 1)	9/14/2010	3/8/2011	9/1/2011	9/30/2011 <i>[Closed to Accrual]</i>	289	N/A
NCCTG_N10CB	3	APPROVED; Revise & Resubmit	A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® versus Placebo in the Prevention of Acute Radiation Enteritis in Patients Receiving Abdominal and/or Pelvic Radiation Therapy	Robert C. Miller MD & Christopher L. Hallemeier, MD	12/20/2011; 3/16/2011 (rev)	1/11/2011	4/12/2011	10/31/2011			N/A
NCCTG_N10C3-A	3	APPROVED; Revise & Resubmit	The Use of Armodafinil (Nuvigil) To Reduce Severe Cancer-Related Fatigue in Patients with Glioblastoma Multiforme: A Randomized, Novel Adaptive Design Study.	Charles Loprinzi, MD	4/29/2011; 8/26/2011	6/14/2011	10/11/2011				N/A
NCCTG_N11C5	3	APPROVED	Phase III, Randomized, Double-Blind Study of Lactobacillus brevis CD2 Lozenges versus Placebo in the Prevention of Acute Oral Mucositis in Patients with Head and Neck Cancer Receiving Concurrent Radiotherapy and Chemotherapy	Charles Loprinzi, MD	8/31/2011	10/11/2011	N/A	2/27/2012			N/A
NCCTG_N10C7	2&3	APPROVED; Revise & Resubmit	A Randomized Double-blind Placebo Controlled, Phase II/III, Study of Aromatase Inhibitors and Transdermal Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgia	Stephen Birrell, MD, PhD	1/14/2011; 06/13/2011	3/8/2011	7/12/2011	3/29/2012			N/A
RTOG-1012	2	APPROVED	Phase II Randomized Dose Seeking Trial of the Prophylactic Use of Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis During the Treatment of Lung Cancer	Lawrence B. Berk, MD	10/20/2009	12/8/2009	N/A	11/23/2010	2/28/2012 <i>[Temporarily closed to Accrual]</i>	27	N/A
RTOG 0938	2	APPROVED; Revise & Resubmit	A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer	Jean-Paul Bahary, MD	3/8/2010; 8/18/2010 (rev)	4/20/2010	9/14/2010	11/23/2010	9/29/2011	102	N/A
RTOG-1203	2	APPROVED; Revise & Resubmit	A Randomized Phase II Study of Three-Dimensional vs. IMRT Pelvic Radiation for Endometrial and Cervical Cancer (TIME-C)	Ann Klopp, MD, PhD	8/18/2011; 11/28/2011	10/11/2011	1/24/2012	2/28/2012	11/28/2012	7	N/A
SWOG_S0927	2	APPROVED; Revise & Resubmit	Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer	Dawn Hershman, MD, MS	4/3/2009	5/12/2009	11/10/2009	10/4/2010	2/1/2012	262	N/A

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual	Accrual Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
SWOG_S1202	3	APPROVED	Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer	Norah L. Henry, MD, PhD	11/1/2011	12/13/2011	N/A	4/10/2012			N/A
URCC-09005 (URCC-10054)	2	APPROVED; Revise & Resubmit	Curcumin for the Prevention of Radiation-Induced Dermatitis in Breast Cancer Patients	Julie Ryan, PhD, MPH	2/19/2009	4/14/2009	12/8/2009	10/25/2010	10/25/2010	695	N/A
WFU-08-03-06	2	APPROVED; Revise & Resubmit	Phase II Randomized Placebo Controlled Study of Armodafinil on Fatigue in Brain Tumor Patients Receiving Brain Radiation Therapy	Edward G. Shaw, MD	3/12/2008	4/8/2008	7/8/2008	12/3/2009	8/5/2010 [Closed to Accrual & Treatment]	54	N/A
WFU-08-08-08	2	APPROVED; Revise & Resubmit	Yoga during Breast Cancer Treatment: Establishing Community-Based Partnerships	Suzanne Danhauer, PhD	8/18/2008	9/9/2008	1/13/2009	6/22/2009	10/21/2009 [Closed to Accrual]	40	N/A
WFU-08-08-09	2	APPROVED; Revise & Resubmit	A Randomized Phase II Dose Finding Study of ArginMax with or without Phosphodiesterase-5 Inhibitors for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy	James Urbanic, MD	8/14/2008	9/9/2008	2/10/2009	3/26/2010	10/18/2010	123	N/A
WFU 10-05-16	2	APPROVED	A Feasibility Study of Donepezil in Breast Cancer Survivors with Chemotherapy-Related Self-Reported Cognitive Dysfunction	Julia Lawrence, DO	5/12/2010	8/10/2010	N/A	10/18/2011	6/6/2012	62	N/A
URCC-12048	2	APPROVED; Revise & Resubmit	Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial (response to URCC 12021)	Oxana Palesh, PhD., MPH	??; 9/19/2012	7/24/2012	10/23/2012				N/A
ALLIANCE_A221 301		APPROVED	Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)	Rudolph M. Navari	3/22/2013	4/23/2013	N/A				N/A
Thoracic Malignancy Steering Committee (TMSC)											
ACOSOG Z41102 (A081105)	3	APPROVED	Personalized Adjuvant Therapy In Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)	Ramaswamy Govindan, MD	3/29/2011	5/5/2011	N/A	In Review 5/3/2012		0	N/A
ECOG_E2511	2	APPROVED; Pending with Revisions	Phase II Randomized Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer	Taofeek K. Owonikoko, MD, PhD	7/20/2011; 10/17/2011 (rev)	8/18/2011	11/10/2011	7/6/2012	9/28/2012	3	N/A
RTOG-1106	2	APPROVED; Pending with Revisions	Randomized Phase II Trial of Individualized Adaptive Radiation Using During-Treatment FDG-PET/CT and Modern Radiation Technology to Dose Escalate in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	Feng Ming (Spring) Kong, MD, PhD	1/4/2011; 4/14/2011 (rev1);	2/17/2011	5/5/2011	In Review 07/08/2011	2/22/2012	10	N/A
RTOG 1021 (formerly ACOSOG Z4099)	3	APPROVED	A Randomized Phase III Study of Sublobar Resection versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)	Hiran C. Fernando, MD (ACOSOG); and Robert Timmerman, MD (RTOG)	2/22/2010	3/18/2010	N/A	4/11/2011	5/2/2011 [Closed to Accrual]	12	N/A
RTOG 0937	2	APPROVED; Pending with Revisions	Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)	Elizabeth Gore, MD	5/7/2009 7/30/2009	5/21/2009	8/20/2009	1/12/2010	3/18/2010	44	N/A

NCI Scientific Steering Committee Approved Concepts (2006 - May 31, 2013)

Cooperative Group/ Document Number	Phase	Status	Document Name	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accural	Accural Total as of 5/31/13	BIQSFP Assay/ Test/ Tool
RTOG 1306/ Alliance 31101	2	APPROVED	A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)	Ramaswamy Govindan, MD (Alliance); Hak Choy, MD	7/18/2012	9/20/2012	N/A				N/A
ECOG-E4512	3	APPROVED; Pending with Revisions	Individualized therapy for surgically resected early stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein	Suresh S. Ramalingam, MD	9/21/2012; 12/07/2012	10/18/2012	12/20/2012				N/A
RTOG-1308	3	APPROVED; Pending with Revisions	Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Radiochemotherapy for Inoperable Stage II-IIIb NSCLC	Zhongxing Liao, MD	10/25/2012; 12/18/2012	11/15/2012	1/17/2013				N/A
SWOG-S1300	2	APPROVED; Pending with Revisions	A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients who have Progressed Systemically after Previous Clinical Benefit from Crizotinib Monotherapy (w/ BIQSFP)	D. Ross Camidge, MD, PhD	11/30/2012 03/04/2013	12/20/2012	3/21/2013				<i>DNA sequencing ALK kinase, ALK FISH, SNaPshot</i>